Adzynma (Adamts13, Recombinant-Krhn) Patent Expiration, LOE Window & CMS Spending

Adzynma (Adamts13, Recombinant-Krhn) by Takeda: Off-Patent Genericized (AB Competition), 0 AB generics, $4.4M 2024 CMS Part D & Medicaid spend, and $3 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTakeda
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$4.4M
2024 Medicare Part D Spend$1.7M
2024 Medicaid Spend$2.7M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($3 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.